Drug developers
Turn access risk into parallel workstreams before authorization.
Road to Access guides
Planning toolDelivery
Psychedelic Therapy Launch-Readiness Checklist
A practical Road to Access checklist for turning a positive clinical and regulatory path into reimbursed, governed, and deliverable psychedelic-assisted therapy.
- Germany access signal
- 1 program
- Checklist lanes
- 8
- Core risk
- Timing
- Public status
- Working
BfArM-listed psilocybin compassionate use, July 2025 to July 2026
Source: BfArM
Evidence, HTA, payment, sites, workforce, data, governance, equity
Access work must start before approval
Scenario tool, not medical or reimbursement advice
At a glance
What to take from this page
- Launch readiness is a system capability, not just a regulatory milestone.
- Evidence, payment, workforce, and site governance need to mature in parallel.
- The checklist is designed to expose missing workstreams early.
Who this helps
Operators
Translate a protocol into sites, people, rooms, data, and governance.
Investors and policy readers
Assess whether the ecosystem is ready for real access rather than only approval.
Launch readiness
Approval is only one lane in the launch system
Each lane needs an owner, cited assumptions, and a concrete path into routine care before a positive decision can become patient access.
Evidence
1Clinical / HEOR
Endpoint, comparator, durability, safety, resource use
HTA
2Market access
Model, uncertainty plan, patient selection, value story
Payment
3Payer / provider
Drug, service, monitoring, registry, and site-cost object
Sites
4Operations
Rooms, pharmacy, escalation, referral, contracting
Workforce
5Clinical governance
Training, supervision, protected time, medical cover
Data
6Evidence operations
Baseline, follow-up, relapse, retreatment, adverse events
Governance
7Provider leadership
Protocol, consent, audit, quality assurance, accountability
Equity
8Payer / policy
Eligibility, geography, wait lists, private spillover
Launch-readiness lanes
| Lane | Question to answer | Evidence of readiness |
|---|---|---|
| Evidence | Do pivotal and follow-up data answer regulator and payer questions? | Endpoints, durability, safety, comparator, and subgroup logic |
| HTA | Can the value case survive national assessment? | Economic model, uncertainty plan, appropriate-use criteria |
| Payment | What exactly is reimbursed? | Drug, preparation, dosing, monitoring, integration, registry, and outcome tracking |
| Sites | Where can care actually happen? | Certified rooms, referral routes, pharmacy, emergency protocols |
| Workforce | Who can safely deliver the pathway? | Training, supervision, availability, medical cover, fidelity |
| Data | How will outcomes and safety be tracked after launch? | Registry, relapse, retreatment, adverse events, resource use |
| Governance | Who is accountable? | Clinical protocols, consent, escalation, audit, quality assurance |
| Equity | Who is excluded by design or cost? | Eligibility, geography, private-payment spillover, waiting-list impact |
How to read the checklist
This checklist is a resource for spotting gaps. It is not a claim that any product, country, or provider is ready today.
The practical question is whether each lane has an owner, cited assumptions, and a pathway from evidence to routine delivery.
Germany shows why partial access is not launch readiness
Germany now has a concrete classic-psychedelic access signal: BfArM lists a psilocybin compassionate-use program for treatment-resistant depression from 11 July 2025 to 11 July 2026, with ZI Mannheim as the responsible institution.
That is not broad routine care. ZI describes exceptional-case treatment in Mannheim and Berlin under the same medical leadership. At ZI, the pathway includes suitability review, psychological preparation and integration, inpatient dosing, and heavy demand.
Germany is useful for launch planning because it separates three workstreams that often get blurred: an approved and reimbursed esketamine precedent, a time-limited psilocybin compassionate-use route, and the still-unresolved payment and delivery design for a future drug-plus-therapy package.